Tuesday, February 28, 2023 9:26:41 PM
Sell the wife’s car and buy a runner.
Binary event is imminent. Who wants to guess the outcome
I say the fda will approve the endpoint change but then ask for more trials.
Stock could gain on that outcome
The alternative is the deny to end point change but if that was the case they would have said so already imo
Binary event is imminent. Who wants to guess the outcome
I say the fda will approve the endpoint change but then ask for more trials.
Stock could gain on that outcome
The alternative is the deny to end point change but if that was the case they would have said so already imo
Recent RVVTF News
- Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases • ACCESS Newswire • 03/11/2026 11:30:00 AM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 12/15/2025 12:30:00 PM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 11/21/2025 05:07:49 PM
- Revive Therapeutics Announces Closing of Second Tranche of Private Placement • GlobeNewswire Inc. • 09/19/2025 09:00:28 PM
